Advertisement
BIIB vs EXAS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and EXAS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileEXAS’s FA Score has 0 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- EXAS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while EXAS’s TA Score has 3 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 4 bearish.
- EXAS’s TA Score: 3 bullish, 6 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -4.91% price change this week, while EXAS (@Medical Specialties) price change was -2.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.97%. For the same industry, the average monthly price growth was +3.29%, and the average quarterly price growth was +10.80%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.65%. For the same industry, the average monthly price growth was +2.06%, and the average quarterly price growth was -2.13%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 22, 2025.
EXAS is expected to report earnings on Oct 29, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+0.97% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Medical Specialties (-0.65% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIIB | EXAS | BIIB / EXAS | |
| Capitalization | 31.3B | 12.8B | 245% |
| EBITDA | 2.04B | 29.3M | 6,956% |
| Gain YTD | -15.845 | -7.083 | 224% |
| P/E Ratio | 26.95 | N/A | - |
| Revenue | 9.84B | 2.5B | 393% |
| Total Cash | 1.05B | 778M | 135% |
| Total Debt | 7.34B | 2.56B | 287% |
BIIB | EXAS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 72 | 97 | |
PRICE GROWTH RATING 1..100 | 61 | 50 | |
P/E GROWTH RATING 1..100 | 97 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXAS's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for BIIB (88). This means that EXAS’s stock grew somewhat faster than BIIB’s over the last 12 months.
EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that EXAS’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's SMR Rating (72) in the Biotechnology industry is in the same range as EXAS (97). This means that BIIB’s stock grew similarly to EXAS’s over the last 12 months.
EXAS's Price Growth Rating (50) in the Biotechnology industry is in the same range as BIIB (61). This means that EXAS’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (97) in the Biotechnology industry is in the same range as EXAS (100). This means that BIIB’s stock grew similarly to EXAS’s over the last 12 months.
| BIIB | EXAS | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 54% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 81% |
| Advances ODDS (%) | 2 days ago 53% | 10 days ago 71% |
| Declines ODDS (%) | 4 days ago 70% | 1 day ago 81% |
| BollingerBands ODDS (%) | 1 day ago 58% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 49% | 1 day ago 78% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EUAD | 43.18 | 0.55 | +1.29% |
| Select STOXX Europe Aerospace & Defense ETF | |||
| SOVF | 30.07 | 0.33 | +1.10% |
| Sovereign's Capital Flourish Fund | |||
| AOR | 61.36 | 0.21 | +0.34% |
| iShares Core 60/40 Balanced Allc ETF | |||
| HF | 20.50 | N/A | N/A |
| DGA Core Plus Absolute Return ETF | |||
| EVN | 10.23 | -0.04 | -0.39% |
| Eaton Vance Municipal Income Trust | |||
BIIB and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +0.18% | ||
| AMGN - BIIB | 57% Loosely correlated | -0.26% | ||
| PFE - BIIB | 48% Loosely correlated | -0.12% | ||
| SNY - BIIB | 46% Loosely correlated | +0.27% | ||
| NVS - BIIB | 44% Loosely correlated | -3.25% | ||
| MRK - BIIB | 44% Loosely correlated | -1.10% | ||
More | ||||
EXAS and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.
| Ticker / NAME | Correlation To EXAS | 1D Price Change % | ||
|---|---|---|---|---|
| EXAS | 100% | -2.72% | ||
| QGEN - EXAS | 55% Loosely correlated | N/A | ||
| RGEN - EXAS | 55% Loosely correlated | +3.58% | ||
| ILMN - EXAS | 34% Loosely correlated | +1.00% | ||
| LH - EXAS | 33% Loosely correlated | N/A | ||
| CDNA - EXAS | 33% Poorly correlated | -38.49% | ||
More | ||||